

Chronic Kidney Disease in Diabetes Mellitus 2 (CKD in DM2) Primary Care [Team] Pathway for Optimizing Kidney and Cardiovascular Outcomes:

For use in Stable Ambulatory Patients over 18 years of age

Quick links:

[Glossary](#)

[Expanded details](#)

[Provider resources](#)

[Patient resources](#)

Adult with type 2 diabetes

Appropriate counselling/use of lifestyle therapies

Change in clinical status or review of diabetes targets

Required Therapy and Targets

- **Metformin** - if indicated
- Ensure optimal cardiorenal protection:
 1. Prescribe **ACE/ARB** if HTN (BP target < 130/80)
 2. Prescribe Statin as per guidelines
 3. Medication reconciliation and relevant de-prescribing e.g., Sulfonylureas

If Red Flags present

Immediate initiation of insulin therapy or transfer to Urgent Care **recommended** if evidence of Metabolic Decompensation, defined as one of more of the following:

1. Unintentional severe weight loss due to diabetes **OR**
2. Marked or symptomatic hyperglycemia **OR**
3. Diabetic Ketoacidosis/Hyperosmotic Syndrome

No red flags

Consider based on history and current visit

Kidney Protection

Prioritize CKD in DM2 with ACR > 3

Note: May also be considered in patients with GFR < 45 and ACR < 3

Optimal kidney protection. Confirm **ACE/ARB** is prescribed to max tolerated dose

- BP target < 130/80

Consider referring to the CKD Pathway for additional guidelines

GFR ≤ 20 (mL/min/1.73m²)?

No

Yes

Consult Nephrology prior to initiating SGLT2i

Heart (CV) Protection

Cardiovascular disease?

Atherosclerotic Cardiovascular Disease (ASCVD) and Multiple Risk Factor (MRF)

Optimal CV protection. Confirm **ACE/ARB** and **Statin** to max tolerated dose

Heart Failure predominates

Ensure optimal guideline directed medical therapy for HF in addition to prescribing SGLT2i

ASCVD/MRF predominates

History of stroke, TIA, heart disease, myocardial infarction, peripheral artery disease; evidence of atherosclerosis; angina

Consider prescribing in combination

1. **SGLT2i**
2. **GLP-1**

GLP-1RA may be preferred where blood sugar lowering/weight loss is priority

Review appropriate **GLP-1** for A1C Optimization

Heart Failure Pathway

DO NOT use GLP-1 and DPP-4i together due to redundant mechanism of action

Reassess patient regularly as per guidelines

A1C Optimization

Target: A1C ≤ 7.0% or individual target

Insulin may be indicated on patients who remain above target despite optimal therapy or in those who have metabolic complications of hyperglycemia

Consider most appropriate care stream based on patient goal(s). Goals listed below.

Reduce weight

Minimize hypoglycemia risk

Reduce blood glucose

Multiple possible agents **GLP1-RA, SGLT2i, DPP4i**
Refer to Diabetes Canada Guidelines

Consider other agents. See Diabetes Canada User's Guide

Consider Endocrinology referral

Prescribe appropriate **SGLT2is** for cardiorenal organ protection or A1C optimization

Safe use: SGLT2is (Sick Day Meds)

Continue monitoring patient per guidelines
Medication reconciliation and relevant de-prescribing

Consider using specialist advice or continue on pathway depending on clinical situation or concern

Pathway Primer

The Chronic Kidney Disease in Diabetes Mellitus 2 (CKD in DM2) Primary Care Team Pathway for Optimizing Kidney and Cardiovascular Outcomes is intended to provide evidence-based guidance to support primary care providers and clinical pharmacists in providing guideline concordant therapy in caring for patients over the age of 18 years-old who are living with diabetes and kidney and/or heart disease within the medical home.

Originally envisioned as a treatment pathway to improve the care and treatment of persons living with kidney disease, it became evident the pathway needed to expand to address treatment of persons living with cardiovascular disease and those requiring Hemoglobin A1C control. The pathway also aims to improve the rate of SGLT2i (sodium/glucose cotransporter-2 inhibitor) prescriptions for appropriate patients.

The provincial working group who developed this pathway includes physician representation from

- Cardiology
- Endocrinology
- General Internal Medicine
- Nephrology
- Primary Care

The Working Group also included Pharmacists working in Diabetes and Kidney Care along with representatives from

- The Kidney Health Section, Medicine Strategic Clinical Network
- The University of Calgary and the University of Alberta Physician Learning Programs
- The Health Quality Council of Alberta
- Members from the University of Calgary's Chronic Kidney Disease (CKD) Pathway team

EXPANDED DETAILS

1. Glossary of Terms

- ACEi – angiotensin converting enzyme inhibitor
- ACR > 3 – albumin creatinine ratio > 3
- ARB – angiotensin receptor blocker
- BP – blood pressure
- CKD – chronic kidney disease
- CV – cardiovascular
- CVD – cardiovascular disease
- DM2 – type 2 diabetes
- DPP 4 – dipeptidyl peptidase-4 inhibitors
- GFR – glomerular filtration rate
- GLP1- RA – glucagon-like peptide 1 receptor agonists
- A1C – hemoglobin A1C
- HTN – hypertension
- SGLT2i – sodium glucose luminal transport inhibitors

2. Definitions

- CKD and DM2 (chronic kidney disease and type 2 diabetes)** – is defined as an ACR > 3
- DM2** – is defined as pre-treatment/historical HgbA1C \geq 6.5%



3. Medications

Metformin

Metformin	Normal dose range	eGFR (mL/min/1.73m ²)		
		≥ 60	≥ 30 to < 60	< 30
Product Monograph	1000mg bid or 850mg tid	No dose adjustment required	<ul style="list-style-type: none">• If initiating, start at 250 – 500mg daily• Titrate based on patient effect• Maximum dose: 1000mg bid• NOTE: eGFR closer to 30, consider lowering dose• If already on Metformin, maintain current dose	<ul style="list-style-type: none">• Consider discontinuing• May consult Nephrology

SGLT2 Inhibitors

Canagliflozin (Invokana ®) Product Monograph	Normal dose range: 100 to 300mg PO OD depending on clinical indication		eGFR (mL/min/1.73m²)		
	Organ protection	A1C optimization	≥ 60	≥ 30 to < 60	< 30
	100mg PO daily for organ protection	Starting dose 100mg PO daily. May increase up to 300mg PO daily for additional A1C control	No dose adjustment required	100mg PO daily is the recommended dose for patients with a GFR< 60	<ul style="list-style-type: none"> Do not initiate at GFR <30, but may continue 100mg PO daily for CKD or Heart Failure. Consider Nephrology consult Discontinue once on dialysis
<p>Clinical Note: Health Canada (2020) approved Canagliflozin for the prevention of progression of diabetic nephropathy in 2020. There is no current Health Canada indication for Canagliflozin and Heart Failure.</p>					
Dapagliflozin (Forxiga ®) Product Monograph	Normal dose range: 5 to 10mg PO OD depending on clinical indication		eGFR (mL/min/1.73m²)		
	Organ protection	A1C optimization	≥ 60	≥ 25 to < 60	< 25
	10mg PO daily for organ protection	Starting dose 5mg PO daily. May increase up to 10 mg daily for additional A1C control	No dose adjustment required	<ul style="list-style-type: none"> No dose adjustment required May continue for heart failure or CKD 	<ul style="list-style-type: none"> Do not initiate at GFR <25; but may continue 10mg PO daily for CKD or Heart Failure Consider Nephrology consult Discontinue once on dialysis
<p>Clinical Note: As of September 1, 2023, Dapagliflozin is listed as a regular benefit. Health Canada (August 2021) expanded the indications for Dapagliflozin to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), and cardiovascular (CV) and renal death in adults with chronic kidney disease (CKD) in patients with or without Type 2 Diabetes.</p>					
Empagliflozin (Jardiance ®) Product Monograph Empagliflozin in Patients with Chronic Kidney Disease	Normal dose range: 10 to 25mg PO OD depending on clinical indication		eGFR (mL/min/1.73m²)		
	Organ protection	A1C optimization	≥ 60	≥ 20 to < 60	< 20
	10mg PO daily for organ protection	Starting dose 10mg PO daily. May increase to 25mg PO daily for additional A1C control	No dose adjustment required	10mg PO daily is the recommended dose for patients with a GFR< 60	<ul style="list-style-type: none"> Do not initiate at GFR <20; but may continue 10mg PO daily for CKD or Heart Failure Consider Nephrology consult Discontinue once on dialysis

SGLT2i weight loss and hypoglycemia risk

Class	Medication	Hypoglycemia		Weight Loss	ABC Formulary	Cardiovascular Outcomes	Renal Outcomes
		Monotherapy	Combo therapy ¹				
SGLT-2 Inhibitors	Dapagliflozin	N/A	Min-mod ¹	1 – 3 kg	Yes	Yes	Yes
	Empagliflozin	Rare	Min-mod ¹	1 – 3 kg	Yes	Yes	Yes
	Canagliflozin	Rare	Rare	1 – 3 kg	Yes	Yes	Yes

¹min-mod (minimum- moderate). Depending on the nature of combination therapy. May be elevated if patient is already well controlled on insulin or a secretagogue.

Legend

Rare hypoglycemia

Considering lowering insulin or SU dose

Alberta Blue Cross

DPP-4 / SGLT2 Inhibitors / GLP-1 Receptors Agonists

Special Authorization Request Form:

<https://www.ab.bluecross.ca/dbl/pdfs/60012.pdf>

As of September 1, 2023, Dapagliflozin is listed as a [regular benefit](#).

Data source for hypoglycemia

Diabetes Canada Guidelines

<https://guidelines.diabetes.ca/cpg/chapter13>



GLP-1 Receptor Antagonists

	Normal dose range	eGFR (mL/min/1.73m ²)		
		> 60	30 to 60	< 30
Dulaglutide (Trulicity®) Product Monograph	<ul style="list-style-type: none"> Initiating dose: 0.75mg SC once weekly For additional glycemic control, dose may be increased by 1.5mg/week at 4 week intervals up to 4.5mg SC weekly 	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> No dose adjustment required Use with caution at < 15mL/min Monitor renal function for transient decline in patients with renal impairment reporting severe gastrointestinal reactions which may worsen the renal function
Liraglutide (Victoza®) Product Monograph	Initiating dose: 0.6mg SC daily for 1 week, then 1.2mg SC daily (max 1.8 mg/day SC)	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> No dose adjustment required; use not recommended < 15mL/min due to limited clinical experience Monitor renal function for transient decline in patients with renal impairment reporting severe gastrointestinal reactions which may worsen the renal function
Semaglutide (Ozempic®) Product Monograph	<ul style="list-style-type: none"> Initiating dose: 0.25mg SC weekly for 4 weeks, then 0.5mg SC weekly; For additional glycemic control may increase by 0.5mg/week at 4 week intervals up to 2mg SC weekly (reference: https://guidelines.diabetes.ca/cpg/chapter13) 	No dose adjustment required	No dose adjustment required	<ul style="list-style-type: none"> No dose adjustment required Use with caution < 30mL/min and use not recommended in patients with end- stage renal disease Consult Nephrology if considering initiation



GLP-1 weight loss and hypoglycemia risk

Class	Medication	Hypoglycemia		Weight Loss	ABC Formulary	Cardiovascular Outcomes	Renal outcomes
		Monotherapy	Combo therapy ¹				
GLP 1 Agonists	Semaglutide inj	Rare	Min-mod ¹	>3 kg	Yes	Yes	Yes ²
	Semaglutide po	Rare	Min-mod ¹	>3 kg	No	No	No
	Dulaglutide	Rare	Min-mod ¹	Monotherapy: 0 – 1 kg	No	Yes	Yes ²
		Rare	Min-mod ¹	Combo therapy with SGLT2i or metformin: 1 – 3 kg			
Liraglutide	Rare	Min-mod ¹	1 – 3 kg	No	Yes	Yes ²	

¹min-mod (minimum- moderate). Depending on the nature of combination therapy. May be elevated if patient is already well controlled on insulin or a secretagogue

²Based on secondary outcomes from cardiovascular trials

Legend

Rare hypoglycemia

Considering lowering insulin or SU dose

Alberta Blue Cross

DPP-4 / SGLT2 Inhibitors / GLP-1 Receptors Agonists

Special Authorization Request Form:

<https://www.ab.bluecross.ca/dbl/pdfs/60012.pdf>

Data source for hypoglycemia

Diabetes Canada Guidelines

<https://guidelines.diabetes.ca/cpg/chapter13>



DPP – 4 Inhibitors

	Normal dose range	eGFR (mL/min/1.73m ²)		
		> 60	30 to 60	< 30
Linagliptin (Trajenta ®) Product Monograph	5mg PO daily	No dose adjustment required	No dose adjustment required	No dose adjustment required Use with caution at ≤ 15mL/min
Sitagliptin (Januvia ®) Product Monograph	100mg PO daily	No dose adjustment required	50mg PO daily at GFR < 45mL/min	25mg PO daily

DPP – 4 weight loss and hypoglycemia risk

Class	Medication	Hypoglycemia		Weight Loss	ABC Formulary	Cardiovascular Outcomes	Renal Outcomes
		Monotherapy	Combo therapy ¹				
DPP-4 Inhibitors	Sitagliptin	Rare	Rare	±	Yes	No	Yes ²
	Linagliptin	Rare	Min-mod	0 – 1 kg	Yes	No	Yes ²

¹min-mod (minimum- moderate). Depending on the nature of combination therapy. May be elevated if patient is already well controlled on insulin or a secretagogue

² Based on intermediate secondary outcomes (e.g., albuminuria reduction) seen in cardiovascular outcome trials, only use when others have not worked

Legend

Rare hypoglycemia

Considering lowering insulin or SU dose

Alberta Blue Cross

DPP-4 / SGLT2 Inhibitors / GLP-1 Receptors Agonists

Special Authorization Request Form:

<https://www.ab.bluecross.ca/dbl/pdfs/60012.pdf>

Data source for hypoglycemia

Diabetes Canada Guidelines

<https://guidelines.diabetes.ca/cpg/chapter13>



4. Medication Reconciliation and Relevant De-prescribing

[Canadian Medication Appropriateness and Deprescribing Network website](#)



**Canadian Medication
Appropriateness and
Deprescribing Network**

Key pages:

- [Do I still need this medication? Is deprescribing for you?](#)
- [Other resources for clinicians – Do I still need this medication? Is deprescribing for you?](#)


[MedStopper](#)

MedStopper is a deprescribing web-based tool developed by a team of health professionals to help doctors and their patients look at a list of medications to decide if some should be stopped or changed.



5. Heart Failure Guidelines

Canadian Cardiovascular Society Heart Failure (HF) guidelines (2021)



<https://pubmed.ncbi.nlm.nih.gov/33827756/>



Practice recommendations for the use of GLP-1RA or SGLT2i for cardiorenal risk reduction in adults

Process	Practice Statement	Strength of Recommendation	Quality of Evidence
Screening	CV specialist are encouraged to assess kidney and glycemic status through measurement of eGFR, UACR, and A1C and to document LVEF when evaluating symptoms of HF.		
	Recommendations		
Treatment of HF	In adults with HF and LVEF \leq 40%, we recommend use of SGLT2i to reduce all cause and CV mortality, hospitalization for HF, and the composite end point of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease.	Strong	Moderate
	In adults with HF and LVEF $>$ 40%, we recommend use of SGLT2i to reduce hospitalization for HF.	Strong	Moderate
Treatment of CKD	In adults with CKD (UACR $>$ 20 mg/mmol, eGFR \geq 25 mL/min/1.73m ²), we recommend use of SGLT2i to reduce the composite of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease, all-cause and CV mortality, nonfatal MI, and hospitalization for HF.	Strong	Moderate
Prevention of cardiorenal events in adults with either T2D and ASCVD or multiple risk factors for ASCVD	In adults with T2D and either ASCVD or multiple risk factors for ASCVD, we recommend use of:		
	A. GLP-1RA or SGLT2i to reduce the risk of all-cause, or CV mortality or MACE;	Strong	Moderate
	B. SGLT2i to reduce the risk of hospitalization for HF or the composite of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease;	Strong	Moderate
	C. GLP-1RA to reduce the risk of nonfatal stroke.	Strong	Moderate

Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults ([https://www.onlinecjc.ca/article/S0828-282X\(22\)00335-X/fulltext](https://www.onlinecjc.ca/article/S0828-282X(22)00335-X/fulltext))



6. Managing Type 2 Diabetes

For more details on Type 2 Diabetes management consult <https://guidelines.diabetes.ca/>

7. A1C Optimization Goals

- Consult [Diabetes Canada | Clinical Practice Guidelines – A1C Target 2018](#) for guidance on individualizing your patients A1C targets.

Weight loss and hypoglycemia risk

Class	Medication	Hypoglycemia		Weight Loss	ABC Formulary	Cardiovascular Outcomes	Renal outcomes
		Monotherapy	Combo therapy ¹				
SGLT-2 Inhibitors	Dapagliflozin	N/A	Min-mod	1 – 3 kg	Yes	Yes	Yes
	Empagliflozin	Rare	Min-mod	1 – 3 kg	Yes	Yes	Yes
	Canagliflozin	Rare	Rare	1 – 3 kg	Yes	Yes	Yes
GLP 1 Agonists	Semaglutide inj	Rare	Min-mod	>3 kg	Yes	Yes	Yes ²
	Semaglutide po	Rare	Min-mod	>3 kg	No	No	No
	Dulaglutide	Rare	Min-mod	Monotherapy 0 – 1 kg	No	Yes	Yes ²
		Rare	Min-mod	Combo therapy with SGLT2i or metformin 1 – 3 kg			
Liraglutide	Rare	Min-mod	1 – 3 kg	No	Yes	Yes ²	
DPP-4 Inhibitors	Sitagliptin	Rare	Rare	±	Yes	No	Yes ³
	Linagliptin	Rare	Min-mod	0 – 1 kg	Yes	No	Yes ³

¹min-mod (minimum- moderate). Depending on the nature of combination therapy. May be elevated if patient is already well controlled on insulin or a secretagogue

²Based on secondary outcomes from cardiovascular trials

³Based on intermediate secondary outcomes (e.g., albuminuria reduction) seen in cardiovascular outcome trials, only use when others have not worked

Legend

Rare hypoglycemia

Considering lowering insulin of SU dose



8. Specialist Referral and Advice Options

- Specialist Link (Calgary Zone)
www.specialistlink.ca
- ConnectMD (Edmonton Zone)
<https://pcnconnectmd.com>
- Alberta Netcare eReferral Electronic Advice Request (Provincial)
www.albertanetcare.ca/eReferral.htm
- Alberta's Pathway Hub for referral, clinical and patient pathways (Provincial Pathways Unit)
www.albertapathways.ca

Cardiology

- Specialist Link Heart Failure Pathway (Calgary)
www.specialistlink.ca/assets/pdf/Cardiology_HeartFailure_Pathway.pdf

Endocrinology

- Calgary
[Primary Care Access to Endocrinology](#)
- Edmonton
[Diabetes Program Information and Referral for Health Professionals](#)

Nephrology

- Provincial Nephrology Referral Quick Reference
www.albertahealthservices.ca/assets/info/hp/arp/if-hp-arp-nephrology-qr.pdf



9. Other Resources

- SGLT-2 Inhibitors, Insulin and Diabetic Ketoacidosis (DKA) (albertahealthservices.ca)
<https://www.albertahealthservices.ca/assets/mha/diabetes/mha-diabetes-sgl-2-inhibitors-insulin-diabetic-ketoacidosis.pdf>
- Diabetes Information - Diabetes Educators Calgary
<https://www.diabeteseducatorscalgary.ca/>
- Diabetes Canada – Clinical Practice Guidelines
<https://guidelines.diabetes.ca/>
- CKD Pathway
<https://www.ckdpathway.ca/>

10. Safe Use of SGLT2is

- Additional resource: <https://guidelines.diabetes.ca/docs/cpg/Appendix-8.pdf>
- Type 2 Diabetes and Sick Days Medications to Pause document. This file is used with permission from the [SADMANS-RX.pdf \(rxfiles.ca\)](#) (contact: RXFiles Info info@rxfiles.ca)



TYPE 2 DIABETES and SICK DAYS MEDICATIONS to PAUSE

This handout is in general accordance with 2018 Diabetes Canada Guidelines.



Name: _____ Date: _____

When you are sick, it is easy to become dehydrated from throwing up, diarrhea, and/or a fever.

If you become dehydrated, your kidneys may be stressed. This can make certain medications cause problems.

This means that **some** medications should be PAUSED when you are sick to prevent side effects or kidney problems.

These medications can then be STARTED AGAIN once you have recovered from being sick.

SIGNS OF DEHYDRATION

- thirst
- unusual tiredness
- dry mouth
- headache
- lightheadedness
- dry/cool skin
- irritability
- confusion
- less peeing

MY PLAN



If I have been throwing up, and/or having diarrhea, and/or a fever and I am worried that I am dehydrated because I cannot keep "anything down", I will PAUSE (temporarily stop) the following medicine(s):

Type of Medication	Your Medication
S sulfonylureas, other secretagogues	<input type="checkbox"/>
A ACE inhibitors	<input type="checkbox"/>
D diuretics*, direct renin inhibitor	<input type="checkbox"/>
M metformin	<input type="checkbox"/>
A angiotensin receptor blockers	<input type="checkbox"/>
N nonsteroidal anti-inflammatory drugs	<input type="checkbox"/>
S SGLT2 inhibitors, or "flozins"	<input type="checkbox"/>

For over-the-counter cough, cold & flu products, please check with your pharmacist first. Do not take any products that contain nonsteroidal anti-inflammatory drugs such as ibuprofen (ADVIL/MOTRIN) or naproxen (ALEVE).

* If using diuretics for heart failure, please contact your physician or health care team for detailed instruction before stopping.

ACE=angiotensin converting enzyme SGLT2=sodium-glucose cotransporter-2

WHEN YOU ARE SICK IT IS OK TO STOP THESE PARTICULAR MEDICINES FOR A FEW DAYS.

REMEMBER TO:

hydrate

try to drink plenty of fluids with minimal sugar, limit caffeine, and consider electrolyte replacement solutions

consult

your health care provider if you have questions about what to do when you are sick or **if you do not feel better after about 3 days**



I will START these medications again at my usual dose when I am feeling well and my body has recovered from the illness.



I will increase the number of times I RECORD (check) my blood glucose levels when I am sick. If they are too high or too low, I will contact my health care provider.

If you are using insulin, you may need to increase or decrease the amount of insulin you inject. For example, you may need to also PAUSE your meal time, short-acting insulin if not eating while sick.

© 2023

RxFiles Academic Detailing
For more tools, visit rxfiles.ca/tools.

Supplementary Information



SADMANS: COMMON medications to temporarily stop with dehydration from throwing up, diarrhea, sweating, etc...				Comments
S	Sulfonylureas, other Secretagogues	gliclazide	DIAMICRON MR	- hold due to reduced clearance of the drug by the kidneys and increased risk of low blood sugars or hypoglycemia
		glimepiride	AMARYL	
		glyburide	DIABETA	
		repaglinide	GLUCONORM	
A	ACE Inhibitors	benazepril	LOTENSIN	- hold due to increased risk for decline in kidney function - note: combination medication products not listed
		captopril	CAPOTEN	
		cilazapril	INHIBACE	
		enalapril	VASOTEC	
		fosinopril	MONOPRIL	
		lisinopril	ZESTRIL	
		perindopril	COVERSYL	
		quinapril	ACCUPRIL	
		ramipril	ALTACE	
	trandolapril	MAVIK		
D	Diuretics	chlorthalidone		- hold due to increased risk for decline in kidney function - special consideration - whether or not to hold diuretics (especially furosemide) in heart failure with short-term illness depends on heart failure and fluid retention status - note: combination medication products not listed
		eplerenone	INSPRA	
		furosemide	LASIX	
		hydrochlorothiazide	HCTZ	
		indapamide	LOZIDE	
		metolazone	ZAROXOLYN	
		spironolactone	ALDACTONE	
Direct Renin Inhibitor	aliskiren	RASILEZ		
M	Metformin	metformin	GLUCOPHAGE GLUMETZA	- hold due to reduced clearance of the drug by the kidneys and increased risk for adverse effects (e.g. more stomach upset) - consider restarting at a lower dose if ongoing nausea and/or diarrhea - note: combination medication products not listed
A	Angiotensin receptor blockers	candesartan	ATACAND	- hold due to increased risk for decline in kidney function - note: combination medication products not listed
		eprosartan	TEVETEN	
		irbesartan	AVAPRO	
		losartan	COZAAR	
		olmesartan	OLMETEC	
		telmisartan	MICARDIS	
	valsartan	DIOVAN		
N	Non-steroidal anti-inflammatory drugs & COXIBS	acetylsalicylic acid (ASA)	ASPIRIN ENTROPHEN	- hold due to increased risk for decline in kidney function - in most situations, it is recommended to continue with low dose ASA during short-term illness - note: combination medication products not listed; as well, over-the-counter cough, cold & flu products that contain these medications are not listed
		celecoxib	CELEBREX	
		diclofenac	VOLTAREN	
		ibuprofen	ADVIL / MOTRIN	
		indomethacin	INDOCID	
		ketorolac	TORADOL	
		naproxen	NAPROSYN / ALEVE	
S	SGLT2 inhibitors or "flozins"	canagliflozin	INVOKANA	- hold due to increased risk for decline in kidney function - note: combination medication products not listed
		dapagliflozin	FORXIGA	
		empagliflozin	JARDIANCE	
		ertugliflozin	STEGLATRO	

ACE=angiotensin converting enzyme SGLT2=sodium-glucose cotransporter

Disclosures: No conflicts of interest are reported.

Disclaimer: RxFiles Academic Detailing is part of the College of Pharmacy and Nutrition at the University of Saskatchewan. The content of this work represents the research, experience and opinions of the authors and not those of the University of Saskatchewan. Neither the authors nor the University of Saskatchewan nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the materials will imply acknowledgment of this disclaimer and release any responsibility of the University of Saskatchewan, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources.

BACKGROUND

About this pathway

The Chronic Kidney Disease in Diabetes Mellitus 2 (CKD in DM2) Primary Care [Team] Pathway for Optimizing Kidney and Cardiovascular Outcomes pathway is for use in stable ambulatory patients over 18 years of age.

Originally envisioned as a treatment pathway to improve the care and treatment of persons with kidney disease, it became evident that the pathway needed to address cardiovascular and endocrinology treatment as well as kidney treatment.

The provincial DKD/SGLT2i working group who developed this pathway includes physician representation (e.g., Cardiology, Endocrinology, General Internal Medicine, Nephrology, Primary Care), representation from the Kidney Health Section, Medicine SCN, the University of Calgary and the University of Alberta Physician Learning Programs, the Health Quality Council of Alberta, Clinical Pharmacists, and members from the CKD Pathway team.

The DKD pathway is intended to provide evidence-based guidance to support primary care providers and clinical pharmacists in providing guideline concordant therapy in caring for patients with diabetes and kidney and/or heart disease within the medical home.

Authors and conflict of interest declaration

- This pathway was reviewed and revised under the auspices of the Kidney Health Section, Medicine SCN in 2023 by a multi-disciplinary team led by nephrologists, cardiologists, general internists, family physicians, endocrinologists, and pharmacists.
- For more information, contact the Kidney Health Section, Medicine SCN at MedicineSCN@ahs.ca.
- Pathway Feedback and Review Process Primary care pathways undergo scheduled review every three years, or earlier if there is a clinically significant change in knowledge or practice. The next scheduled review is April 2026, however, we welcome feedback at any time. Click on the Provide Feedback button to provide your feedback.

[Provide Feedback >](#)

Pathway review process, timelines

- Created and approved August 2023
- Next review April 2026

Copyright information

This work is licensed under a Creative Commons Attribution-Non-commercial-Share Alike 4.0 International license. You are free to copy, distribute, and adapt the work for non-commercial purposes, as long as you attribute the work to Alberta Health Services and Primary Care Networks and abide by the other license terms. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same, similar, or compatible license. The license does not apply to content for which the Alberta Health Services is not the copyright owner.



DISCLAIMER

This pathway represents evidence-based best practice but does not override the individual responsibility of health care professionals to make decisions appropriate to their patients using their own clinical judgment given their patients' specific clinical conditions, in consultation with patients/alternate decision makers. The pathway is not a substitute for clinical judgment or advice of a qualified health care professional. It is expected that all users will seek advice of other appropriately qualified and regulated health care providers with any issues transcending their specific knowledge, scope of regulated practice or professional competence.

PROVIDER RESOURCES

Clinical Practice Guidelines

Description	Website
Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults	www.sciencedirect.com/science/article/abs/pii/S0828282X2200335X?via%3Dihub
Canadian Cardiovascular Society heart failure (HF) guidelines (2021)	https://pubmed.ncbi.nlm.nih.gov/33827756/
Diabetes Canada Clinical Practice Guidelines Expert Committee. Chronic Kidney Disease in Diabetes. McFarlane, P. et al (2018).	http://guidelines.diabetes.ca/cpg/chapter29
Diabetes Canada Clinical Practice Guidelines Quick Reference Guide (Updated 2020)	https://guidelines.diabetes.ca/CDACPG/media/documents/CPG/CPG_Quick_Reference_Guide_PRINT_EN_2021.pdf
Guidelines Diabetes Canada	http://guidelines.diabetes.ca/cpg
Top10 Takeaways for Clinicians from the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD	https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Diabetes-Management-in-CKD-Guideline-Top-10-Takeaways-for-Patients.pdf

References

Description	Website
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 63, 221–228. Buse, J.B., et al (2019, December 19).	https://diabetesjournals.org/care/article/43/2/487/36098/2019-Update-to-Management-of-Hyperglycemia-in-Type
Cardiovascular Protection with Diabetes Quick Reference	https://guidelines.diabetes.ca/docs/resources/prescription-for-cardiovascular-protection-with-diabetes.pdf
Diabetes Canada Quick Reference Guide (2020)	https://guidelines.diabetes.ca/cpg-reference-guide
Empagliflozin in Patients with Chronic Kidney Disease	https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
My Diabetes Care	https://guidelines.diabetes.ca/docs/patient-resources/my-diabetes-care-not-just-about-blood-sugar.pdf
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant, 34, 208–230. Sarafidis, P., et al (2019).	https://academic.oup.com/ndt/article/34/2/208/5307730?login=true

Resources

Description	Website
Advance Care planning	www.albertahealthservices.ca/info/Page9099.aspx
Atrial Fibrillation	www.specialistlink.ca/assets/pdf/Cardiology_AFIB_Pathway.pdf
CADTH reimbursement recommendation: Dapagliflozin (August 2023)	www.cadth.ca/sites/default/files/DRR/2023/SX0749/%0bRecommendation%20and%20Reasons.pdf
Canadian Medication Appropriateness and Deprescribing Network website	www.deprescribingnetwork.ca/algorithms
Heart Failure	www.specialistlink.ca/assets/pdf/Cardiology_HeartFailure_Pathway.pdf
My Kidneys My Health	https://mykidneysmyhealth.com/
Primary Care Access to Endocrinology	www.specialistlink.ca/assets/pdf/endocrinology/Endocrinology_AccessPathway.pdf
Provincial Nephrology Referral Quick Reference	www.albertahealthservices.ca/assets/info/hp/arp/if-hp-arp-nephrology-qr.pdf
SADMANS	www.rxfiles.ca/RxFiles/uploads/documents/SADMANS-Rx.pdf
Updates to the Alberta Drug Benefit List (September 1, 2023)	https://idbl.ab.bluecross.ca/idbl/DBL/sep_dblupdate.pdf?_gl=1*pht0mf*_%0bga*MTQ5NjIwMjg2OC4xNjIyNTY0MTY4*_ga_L344K4V4H4*MTY5Mz11%0bNTk5Mi40MC4xLjE2OTMyNTYzMiUuNTluMC4w

PATIENT RESOURCES

Information

Description	Website
Advance care planning	https://myhealth.alberta.ca/HealthTopics/Advance-Care-Planning
Alberta Healthy Living Program	www.albertahealthservices.ca/info/page13984.aspx
My Diabetes Care	https://guidelines.diabetes.ca/docs/patient-resources/my-diabetes-care-not-just-about-blood-sugar.pdf
My Health Alberta	https://myhealth.alberta.ca/
My Kidneys My Health	https://mykidneymyhealth.com/
SADMANS	www.rxfiles.ca/RxFiles/uploads/documents/SADMANS-Rx.pdf

Services available

Description	Website
Referral to a registered Dietitian	<ul style="list-style-type: none">• Visit Alberta Referral Directory and search for nutrition counselling.• To learn more about programs and services offered in your zone, visit Nutrition Services.• Health Link has Registered Dietitians available to answer nutrition questions. If a patient has nutrition-related questions, they can call 8-1-1 and ask to talk to a Dietitian.
Services for patients with chronic conditions (Alberta Healthy Living Program – AHS)	www.albertahealthservices.ca/info/page13984.aspx
Supports for working towards healthy lifestyle goals and weight management (Weight Management – AHS)	www.albertahealthservices.ca/info/Page15163.aspx